ThyroSeq v2 claims high positive (PPV) and negative (NPV) predictive values in a wide range of pretest risks of malignancy in indeterminate thyroid nodules (ITNs) (categories B-III and B-IV of the Bethesda system). We evaluated ThyroSeq v2 performance in a cohort of patients with ITNs seen at our Academic Cancer Center from September 2014 to April 2016, in light of the new diagnostic criteria for non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Our study included 182 patients (76% female) with 190 ITNs consecutively tested with ThyroSeq v2. Patient treatment followed our institutional thyroid nodule clinical pathway. Histologies of nodules with follicular variant papillary thyroid carcinoma or NIFTP diagnoses were reviewed, with reviewers blinded to molecular results. ThyroSeq v2 performance was calculated in nodules with histological confirmation. We identified a mutation in 24% (n = 45) of the nodules. Mutations in RAS were the most prevalent (n = 21), but the positive predictive value of this mutation was much lower (31%) than that in prior reports. In 102 resected ITNs, ThyroSeq v2 performance was as follows: sensitivity 70% (46-88), specificity 77% (66-85), PPV 42% (25-61) and NPV 91% (82-97). The performance in B-IV nodules was significantly better than that in B-III nodules (area under the curve 0.84 vs 0.57, respectively; P = 0.03), where it was uninformative. Further studies evaluating ThyroSeq v2 performance are needed, particularly in B-III.
Introduction
Several molecular marker tests are available to refine the diagnosis of thyroid nodules with indeterminate cytology. Initially, these tests were classified as either 'rule-in' or 'rule-out' tests, depending on their ability to identify either cancerous or benign nodules before surgery, and their performance was highly dependent on the prevalence of malignancy . A more recent generation of molecular tests, including ThyroSeq Endocrine-Related Cancer (2017) 24, 127-136 24:3 v2 (University of Pittsburgh Medical Center, Pittsburgh, PA. USA), claims to identify both cancerous and benign nodules with a very high level of confidence and to have a consistent performance over a wider range of prevalence of malignancy than previously available tests (Nikiforov et al. 2014 , Labourier et al. 2015 , Nikiforov et al. 2015 . Despite a lack of independent validation studies, these newer tests are already being marketed and are actively changing the clinical management of ITNs. Moreover, it has recently been proposed to reclassify the encapsulated, non-invasive, follicular variant papillary thyroid carcinoma (FVPTC) as non-invasive follicular thyroid neoplasm with papillarylike nuclear features (NIFTP) . This change in the nomenclature intentionally removes the word 'carcinoma' from the diagnosis to acknowledge the indolent behavior of these tumors. If NIFTPs are considered 'benign', the prevalence of malignancy among ITNs will decrease significantly, influencing the performance of molecular marker tests (Strickland et al. 2015 . A decrease in the pretest prevalence of malignancy will decrease the positive predictive value (PPV) and increase the negative predictive value (NPV) of all molecular tests. However, the specific impact on these tests will depend on the proportion of NIFTPs identified as 'benign' or 'malignant' by each test. In light of this new classification, we evaluated ThyroSeq v2 performance in ITNs (Bethesda category III (B-III), atypia/follicular lesion of undetermined significance or Bethesda category IV (B-IV), follicular/Hürthle cell neoplasm).
Materials and methods

Study cohort
Between September 2014 and April 2016, we evaluated 192 consecutive ITNs in 184 patients with ThyroSeq v2. Two specimens (1%) had complete test failure due to low cellularity and were excluded from the study. Demographic, clinical and pathological information was collected prospectively for 40 patients (22%) who consented to participate in an institutional review boardapproved observational study initiated in July 2015 and was retrieved retrospectively under another institutional review board-approved study with waiver of consent for the remaining samples. We cataloged the following variables that might have an impact on molecular marker test results and/or on resection rates: age at cytological diagnosis; gender; presence of multinodular goiter (defined as the presence of at least 2 nodules >5 mm) or significant bilateral nodules (defined as the presence of at least one contralateral nodule >1 cm); thyroid function test (normal = thyroid-stimulating hormone within reference range; hypothyroidism = thyroid-stimulating hormone above reference range, or patient on LT4 treatment; hyperthyroidism = thyroid-stimulating hormone below reference range or patient on anti-thyroidal drugs); nodule size (as determined by the largest diameter on ultrasound) and cytological diagnosis.
Pathology
All cytological specimens were interpreted by boardcertified cytopathologists in the Department of Anatomic Pathology at Moffitt Cancer Center following the Bethesda system for reporting thyroid cytopathology, and each had a diagnosis of B-III or B-IV. Of the 190 patients with valid test results, 102 (54%) have been resected as of April 30th 2016. All but 2 (2%) of the histological diagnoses were rendered by head and neck pathology faculty at our institution. Although these pathologists were not blinded to the cytological diagnosis or molecular results, standard World Health Organization criteria were utilized in all cases. We began using the NIFTP designation in 2015 for encapsulated FVPTC after the 2015 United States and Canadian Academy of Pathology annual meeting (March 21-27, Boston, MA, USA), when the terminology was proposed in a companion meeting of the Endocrine Pathology Society (Tallini 2015) . Because the definitive diagnostic criteria for NIFTP were not published until August 2016, the histology of all nodules originally diagnosed as FVPTC or NIFTP for which tissue was available, were reviewed by 2 pathologists (L K and B A C) blinded to the molecular results to ensure compliance with current diagnostic criteria. Slides were available for review in 7 of 8 tumors originally classified as NIFTP and 5 were reclassified as benign neoplasms upon review, as they were considered not to display sufficient nuclear atypia (score 1) to make this diagnosis (cytology was B-IV in 1 and B-III in 4; molecular markers were positive (RAS mutation) in 2 and negative in 3). All 6 tumors originally classified as FVPTC were reviewed and 2 were reclassified as NIFTP. Cytology-histology correlation was conducted by matching the location and size of the tumor from ultrasonographic scans and in the macroscopic description in the histology result. Only the histology of the biopsied nodule was used to calculate test performance.
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Sample collection for ThyroSeq v2 and interpretation of results
Molecular marker tests for ITNs have been incorporated in our institutional thyroid nodule evaluation pathway since February 2014. Since that time, oncogene panel evaluation has been offered to all patients with ITNs who underwent biopsy at our institution. ThyroSeq v2 has been our chosen test since September 2014, due to its reported high sensitivity and specificity, yielding a theoretically superior performance in our institution compared to other tests, as previously reported (Valderrabano et al. 2016) . The necessary specimens were collected in an identical fashion either at the radiology department or at the endocrine thyroid nodule clinic using 25 or 27 gauge needles, and the needle hub lavage of each aspirate (usually 5) was included in the media supplied by CBL Path (Rye Brook, NY, USA) for specimen preservation at the time of the ultrasound-guided biopsy. The specimen was stored in a freezer at −22°C until cytological diagnosis was available. If the cytology was indeterminate (B-III or B-IV), the specimen was shipped for analysis. Otherwise, it was discarded. The cytological and molecular specimens of 5 nodules (2.6%) were collected at an outside institution. ThyroSeq v2 results were considered positive when a mutation in BRAF, TP53, AKT1, CTNB1, PIK3CA, TERT or RET genes was identified at an allelic frequency ≥5%; or ≥10% if the mutation was identified in HRAS, KRAS, NRAS, PTEN, TSHR or EIF1AX genes (Nikiforov et al. 2014 , Nikiforov et al. 2015 . Gene fusions were considered positive as previously described (Nikiforov et al. 2014 , Nikiforov et al. 2015 . Nodules with MET overexpression in which the estimated cancer risk was ~40% (n = 2); and nodules 'suspicious for ALK rearrangement' (n = 1) (due to disproportionately strong expression of the ALK tyrosine kinase domain over the extracellular domain), were also considered test-positive. Table 1 summarizes the molecular alterations identified by ThyroSeq v2 in our cohort. Specimens with detected somatic mutations below these thresholds or without molecular alterations identified were considered negative, as in prior publications (Nikiforov et al. 2014 , Nikiforov et al. 2015 . Parathyroid hormone (PTH) gene overexpression (n = 1), 
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sodium-iodine symporter overexpression (n = 2) and specimens with PTEN mutation in patients with documented germ-line mutation (Cowden syndrome (n = 2)) were also considered negative.
Statistical analyses
Analysis cohort comparisons were made with Fisher's exact test for categorical variables and the Van der Waerden test for continuous variables. Logistic regression was used to test the association between the features and test results, and between the features and resection status. Odds ratios and 95% confidence intervals are shown for variables with a significant association. All P values are 2-sided unless otherwise stated and considered statistically significant at the 0.05 level. Sensitivity, specificity, NPV and PPV with exact binomial 95% confidence intervals were calculated for resected nodules only in 3 different cohorts: (1) all indeterminate thyroid nodules, (2) B-III specimens only and (3) B-IV specimens only. As NITFP are likely tumors in transformation on an adenoma-to-carcinoma sequence, these tumors do not clearly fit into a binary benign or malignant classification system. Recognizing this unsolved dilemma, we assessed the performance of ThyroSeq v2 in two different scenarios: (A) considering NIFTP 'malignant' (classical approach used in the validation studies for rule-in tests) and (B) considering NIFTP 'benign'. For ThyroSeq v2 performance comparisons between B-III and B-IV aspirates, ROC curves were calculated and the areas under the curves (AUC) were compared. The test statistic followed a chi-squared distribution: chi-squared = (AUC 1 − AUC 2 ) 2 /(s 1 2 + s 2 2 ), where AUC 1 and AUC 2 are the areas under the 2 independent ROC curves and s 1 and s 2 are their respective standard errors. All statistical analyses were performed using SAS (version 9.4, SAS Institute, Cary, NC, USA).
Results
The baseline characteristics of the 182 patients and 190 nodules tested with ThyroSeq v2 are shown in Table 2 . The test was positive in 45 (23.7%) and negative in 145 (76.3%) nodules. There were no significant differences in any of the clinical characteristics between the test-positive and test-negative groups. Test-positive nodules were more frequently resected than test-negative nodules (2) 53 (77) 58 (18) 33 (1) 50 (1) 76 (34) 20 (9) 2 (1) 2 (1) 73 (25) 78 (7) 100 (1) - (0) 82 (112) 16 (22) 1 (2) 1 (1) 46 (52) 50 (11) -(0) 100 (1) MNG a Significant bilateral MNG b 66 (120) 32 (59) 48 (58) 54 (32) 69 (31) 27 (12) 65 (20) 67 (8) 65 (89) 34 (47) 43 (38) (86) 50 (52) 58 (50) 49 (22) 51 (23) 73 (16) 74 (17) 57 (82) 43 (63) 44 (36) (11) Two patients had 1 nodule with mutation and ≥1 nodule without mutation; both are included in the test-positive cohort. Three nodules in this series measured ≤1 cm in largest diameter, and none had surgical follow-up. One had a TSHR mutation, another one had a BRAF-V600E mutation at low allelic frequency (4% and considered test negative), and no molecular alterations were identified in the other one. All other nodules were >1 cm. No association was found between any of the variables evaluated and the test result. a MNG = at least 2 nodules >5 mm in the thyroid gland. b Significant bilateral MNG = at least one nodule >1 cm in the contralateral lobe to the biopsied nodule. c Nodules with a positive test result were more likely to be resected (P = 0.0004). d Larger nodules were more likely resected (P = 0.048, OR 1.26 (1.00-1.58)), but only among test-negative nodules (P = 0.02, OR 1.36 (1.05-1.76)). Other variables were not significantly associated with the resection rates in any of the cohorts. ITN, indeterminate thyroid nodule; MNG, multinodular goiter; N/A, not available.
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(73.3% vs 47.6%, P = 0.0004). Twelve patients with an identified mutation have not yet undergone thyroid surgery. Five patients with mutations less specific for cancer (3 with TSHR (1 B-IV and 2 B-III) and 2 with EIF1AX (1 B-IV and 1 B-III) mutations) have elected follow-up with observation. Of the 7 patients with unresected nodules exhibiting more cancer-specific mutations (2 with NRAS, 1 with NRAS and EIF1AX, 2 with HRAS, 1 with TERT and 1 with PAX8/PPARG): 2 are scheduled for surgery; 1 had a concomitant unresectable lung cancer with decision not to operate on the thyroid and 4 have been lost to follow-up after having recommended surgery. Larger nodules were also more often resected (P = 0.048; OR 1.26 (1.00-1.58)), but the association between size and resection rates was seen only in the test-negative nodules (P = 0.02; OR 1.36 (1.05-1.76)), not in the test-positive group. The association between all other analyzed variables and rate of resections did not reach significance in any of the cohorts.
Twenty percent of the 102 resected nodules were malignant: 5 NIFTP (25%), 4 FVPTC (20%), 5 conventional variant of papillary thyroid carcinoma (CVPTC) (25%), 1 oncocytic variant of papillary thyroid carcinoma (5%), 4 minimally invasive follicular thyroid carcinomas (FTC) (20%), 1 of them oncocytic variant and one medullary thyroid carcinoma (5%) with an atypical BRAF L597V mutation and calcitonin gene overexpression. No mutations were identified in 5 of the malignancies (25%) (2 NIFTP, 2 CVPTC and 1 minimally invasive FTC), and a KRAS mutation was identified at a low (8%) allelic frequency in one FVPTC that was neither encapsulated nor well circumscribed, therefore, not meeting the criteria for NIFTP diagnosis (Table 3) . RAS mutations were the most common genetic alteration, identified in 21 (47%) of the 45 patients with a positive result (NRAS in 14, HRAS in 4 and KRAS in 3). Of the 16 RAS-mutant nodules resected, 5 (31%) were malignant (1 NIFTP, 2 FVPTC, 1 CVPTC and 1 minimally invasive FTC), falling to 4 (25%) if we consider the NIFTP 'benign'. Table 4 shows the distribution of positive and negative molecular results by histopathologic diagnosis.
The overall performance of ThyroSeq v2 is described in the Figure 1 (cohort 1) . The sensitivity, specificity, PPV and NPV rates considering NIFTP malignant (scenario A) are 70%, 77%, 42% and 91%, respectively. If NIFTP was considered 'benign' (scenario B), the prevalence of malignancy fell from 20% to 15%, and the sensitivity, specificity, PPV and NPV are 73, 75, 33 and 94%, respectively. The performance of ThyroSeq v2 was significantly better (P = 0.03) in B-IV than that in B-III specimens in both scenarios (A and B) , where the AUC of the ROC curves were 0.84 vs 0.57 and 0.85 vs 0.55. ThyroSeq v2 was essentially uninformative for nodules with a B-III diagnosis (Fig. 1, cohort 2) . A negative result in the B-III category did not reduce the prevalence of malignancy significantly in either of the scenarios (false-negative rate similar to prevalence of malignancy). Similarly, a positive result did not significantly increase the prevalence of malignancy, which was 19% in the best-case scenario (scenario A). The test was more informative in B-IV nodules (Fig. 1, cohort 3) . The NPV was higher in B-IV than that in B-III specimens despite having a prevalence of malignancy twice that of B-III, achieving a false-negative rate of ~5% or less in both scenarios (Fig. 1, cohort 3) . The PPV in B-IV was lower than that previously reported (65% and 53% in scenarios A and B, respectively) though a positive result increased the risk of malignancy 2.5-fold.
Discussion
We evaluated ThyroSeq v2 performance in ITNs and found that in our B-III cohort, the test was clinically uninformative, with no significant difference between the pretest and post-test rates of malignancy. In contrast, ThyroSeq v2 achieved a PPV of 65% and a NPV of 94% in B-IV specimens. In this subset of ITNs, the NPV may be high enough to consider observation in lieu of surgery (Nikiforov et al. 2014 , NCCN 2015 . These differences in ThyroSeq v2 performance with previous studies highlight the need for further studies across a range of institutions, to bring the performance of ThyroSeq v2 into a sharper focus.
Strengths and limitations of the study
This study is partly retrospective in nature, and the original histological diagnoses were not blinded to the cytological or molecular results, introducing the potential for ascertainment bias. Our conclusions are therefore somewhat limited by this design. However, this limitation PosiƟve (n = 17) 11 6
NegaƟve (n = 33) 2 31 
24:3
applies equally to the original clinical validation studies for ThyroSeq v2 (Nikiforov et al. 2014 , Nikiforov et al. 2015 . In our study, all cytological reports and 98% of the histological diagnoses were issued by highly experienced endocrine pathologists. Nonetheless, we acknowledge that the expertise of the pathologists cannot eliminate the limitations of light microscopy, especially among follicular pattern lesions (Hirokawa et al. 2002 , Lloyd et al. 2004 , Elsheikh et al. 2008 , Cibas et al. 2013 ). All cases included in this study were consecutively resected, and all molecular studies were performed prospectively before surgery. Molecular markers have been incorporated in our institutional thyroid nodule evaluation pathway for several years. We have elected to use the results primarily to guide the extent of thyroidectomy, rather than to promote observation for negative results for 3 reasons: (1) the lack of independent validation studies confirming the NPV of ThyroSeq v2, (2) our prior experience with a 7-oncogene panel that revealed worse than predicted performance and (3) our relatively high institutional prevalence of malignancy in ITNs previously reported (~30%) (Valderrabano et al. 2016) . Negative predictive values have been consistently under evaluated in independent validation studies of molecular marker tests due to their much lower rates of resection (typically ~10-20%) (Nishino 2016) . In the original ThyroSeq v2 validation studies, the rate of resection of test-negative ITNs was 16% in the B-III study, and not reported in the B-IV study (Nikiforov et al. 2014 , Nikiforov et al. 2015 . We frequently offered diagnostic surgery to our patients with mutation-negative nodules, but treatment options were always discussed with the patient and resection rates were significantly lower when ThyroSeq v2 results were negative. However, almost 50% of ITNs with negative molecular test results were resected in our study, providing a better approximation to the true NPV of the test in our population.
The small sample size of our study (102 resected nodules) results in broad 95% confidence intervals, particularly when the B-III and B-IV specimens are analyzed individually. Nevertheless, our sample size is similar to that of the original validation studies, which included 143 and 98 resected nodules, respectively (Nikiforov et al. 2014 , Nikiforov et al. 2015 . Indeed, broad confidence intervals are seen in all of the extant studies of molecular markers in ITNs, stressing the ongoing need for larger, independent, multicenter, clinical validation studies.
We blindly reviewed all the original FVPTC/NIFTP diagnoses, with the exception of one NIFTP, for which the specimen was not available. This review was performed for 2 reasons: (1) to ensure that the NIFTP diagnosis was made according to the recently published criteria and (2) to minimize any possible bias that knowledge of the molecular result might have had on the interpretation of follicular pattern lesions.
ThyroSeq v2 was uninformative in B-III specimens and the PPV lower than previously reported
ThyroSeq v2 was uninformative in our B-III cohort as the pretest prevalence of malignancy (13%) was not significantly modified by either a positive (19%) or negative (11%) result. Although we cannot conclude that the NPV in our study is significantly different from that in the previous publication (the 95% confidence intervals overlap: 74-97% in our B-III cohort vs 79-100% in the previous publication), the relatively high false-negative rate may preclude the use of observation in lieu of surgery if the test is negative (NCCN 2015 , Nikiforov et al. 2015 . In contrast, the NPV achieved in B-IV specimens (94%) was similar to that previously reported and high enough to justify observation in lieu of surgery in test-negative nodules (Nikiforov et al. 2014) .
Our PPV was lower than reported in previous validation studies, particularly in the B-III cohort, where the difference was significant (95% confidence intervals do not overlap: 4-46% in our B-III cohort vs 61-93% in the previous publication) (Nikiforov et al. 2014 , Nikiforov et al. 2015 . These results are unlikely to change significantly with higher rates of resection of test-positive nodules. Five of 12 unresected ITNs with positive molecular results had mutations with low specificity for cancer (TSHR and EIF1AX), whereas the other 7 had more specific mutations. Even if we consider these 7 unresected nodules with more specific mutations to be truly malignant, the PPV would remain lower than that reported in prior validation studies (~53% overall in best-case scenario, scenario A) (Nikiforov et al. 2014 , Nikiforov et al. 2015 .
Differences between our study and the previous study in B-III nodules are likely to reflect differences in the cytological and molecular characteristics of the B-III cohorts. The B-III rate of malignancy in the current study (13%) was lower than that in our earlier publication (30%) and closer to reported national rates of malignancy for this category (Bongiovanni et al. 2012 , Valderrabano et al. 2016 . The reclassification of 5 NIFTPs as benign in this study and the implementation 24:3 of a consensus review of all B-III diagnoses in 2014 to increase consistency and reduce the diagnostic rate of this category are likely responsible for these differences. However, the lower rate of malignancy alone is unlikely to explain the poor performance of ThyroSeq v2 among B-III specimens. In fact, a lower pretest prevalence of malignancy would be expected to improve the NPV, whereas in our study, the NPV was lower in the B-III than that in the B-IV category, despite the prevalence of malignancy being half that in B-IV.
The B-III group is a heterogeneous category by design, encompassing several scenarios that are associated with various risks of malignancy and likely different prevalence of mutations (Nishino & Wang 2014) . We found a significantly higher rate of test-positive nodules among B-III specimens than that in the prior validation study (21% vs 7%) (Nikiforov et al. 2015) . We hypothesize that this reflects differences in the cytological characteristics of the B-III cohorts that contribute to the discrepancy in ThyroSeq v2 performance. Some scenarios included in the B-III category, such as Hürthle cell predominance, are known to impair the performance of other molecular tests; and this or other scenarios might also affect ThyroSeq v2 performance (Harrell & Bimston 2014 , Brauner et al. 2015 . Future studies are required to clarify these questions.
Impact of NIFTP reclassification on the results interpretation
Upon review of histological specimens blinded to the molecular results, 5/7 (71%) NIFTPs were reclassified as benign neoplasms when a qualitative scale (scoring system) was applied ). This scoring system is still subject to personal interpretation but seems to improve the detection of mutation-positive tumors and standardizes the degree of nuclear atypia needed to make the diagnosis ). Had we relied on the original diagnoses, the prevalence of malignancy would be higher, but the test performance would not be significantly different. Under these circumstances, the sensitivity, specificity, PPV and NPV in scenario A (in which NIFTP is considered malignant) would be 64, 78, 48 and 87%, respectively, in the entire cohort; 45, 73, 31 and 83% in the B-III specimens and 79, 83, 65 and 91% in the B-IV specimens.
As reported by others, RAS mutations were the most common genetic abnormalities found in our series of ITNs (Nikiforov et al. 2014 , Nikiforov et al. 2015 . Mutations in RAS genes are traditionally associated with ~80% risk of malignancy (Gupta et al. 2013 , Radkay et al. 2014 ). However, the most common malignancy among RASmutant tumors is the former encapsulated non-invasive FVPTC, recently reclassified as NIFTP (Gupta et al. 2013 ). If we only considered malignant tumors with invasive features, the rate of malignancy would drop from 83% to 33% in a previously reported series of 63 resected RASmutant tumors, similar to the rate observed in our series (25%) (Gupta et al. 2013) . Only 1 (6%) of 16 resected RAS mutants had a sufficient degree of atypia to merit the NIFTP diagnosis in our series. It is unknown what proportion of the reported FVPTCs among resected RAS mutants in prior series would fulfill the recently proposed criteria for 'significant atypia' ). Altogether, it seems likely that differing NIFTP (nuclear atypia) diagnostic thresholds are one of the main factors in the test performance variability among different studies, given that the rate of invasive neoplasms is fairly consistent, at least among RAS-mutant tumors.
Of 33 resected mutation-positive nodules, 7 (26%) were hyperplastic/adenomatous nodules, a finding consistent with other series (Radkay et al. 2014) . Although histopathological diagnosis of benign lesions depends on morphometric evaluation, oncogene panels offer information on clonality. Although the natural history of benign clonal lesions if left in situ is presently unknown, these may progress over time and acquire malignant potential. At one extreme of this spectrum are NIFTPs, which are considered surgical disease at this time, because invasiveness can only be excluded after adequate evaluation of the entire capsule interface . Although NIFTPs are considered as surgical disease, it might be reasonable to consider molecular marker test results as true positives or false negatives.
We identified 6 false-negative results in our series. In these nodules, cytohistological correlation is reliable due to concordance of size and location in 5 cases and to concordant location and absence of other nodules in the smallest one. In all cases, the epithelial cell control reported by ThyroSeq v2 was adequate, although it was reported borderline in 2, including one CVPTC with extrathyroidal extension that was biopsied and resected elsewhere. Two of these false-negative tumors were NIFTPs. Although the prognosis of these tumors is excellent once resected, their natural history if left in situ is as unknown as for mutation-positive NIFTPs, and therefore, we believe the same considerations regarding surgical resection and molecular marker test results interpretation should apply.
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Conclusion
Our study suggests that ThyroSeq v2 is informative for nodules in the B-IV category, achieving a NPV robust enough to consider observation in lieu of surgery. However, the PPV of the test was lower than expected; and its performance particularly in B-III specimens may be variable among centers. In our institution, ThyroSeq v2 is unlikely to be informative in this category. These differing findings are likely to be explained by several factors including heterogeneity of the B-III category and differences in the diagnostic threshold for NIFTP between pathologists. These factors seem to affect the prevalence of mutation as well as the prevalence of malignancy within the population tested, therefore influencing the performance of the molecular tests and on the interpretation of their results. Validation studies at an institutional level may be necessary to adequately assess the predictive values of each test. Further studies evaluating the performance of ThyroSeq v2 in indeterminate thyroid nodules, particularly in B-III specimens, are needed. 
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